Michael A Pulsipher
Overview
Explore the profile of Michael A Pulsipher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
249
Citations
8494
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Lamble A, Moskop A, Pulsipher M, Maude S, Summers C, Annesley C, et al.
Transplant Cell Ther
. 2023 Sep;
29(11):674-684.
PMID: 37689393
Although CD19-directed chimeric antigen receptor (CAR) T cell therapy (CAR-T) for relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) has been transformative in inducing and sustaining remission, relapse rates remain unacceptably...
22.
Chandrasekaran P, Han Y, Zerbe C, Heller T, DeRavin S, Kreuzberg S, et al.
J Allergy Clin Immunol
. 2023 Sep;
152(6):1619-1633.e11.
PMID: 37659505
Background: Chronic granulomatous disease (CGD) is caused by defects in any 1 of the 6 subunits forming the nicotinamide adenine dinucleotide phosphate oxidase complex 2 (NOX2), leading to severely reduced...
23.
Leiding J, Arnold D, Parikh S, Logan B, Marsh R, Griffith L, et al.
Blood
. 2023 Aug;
142(24):2105-2118.
PMID: 37562003
Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by life-threatening infections and inflammatory conditions. Hematopoietic cell transplantation (HCT) is the definitive treatment for CGD, but questions remain regarding patient...
24.
Myers R, Jacoby E, Pulsipher M, Pasquini M, Grupp S, Shah N, et al.
Transplant Cell Ther
. 2023 Jul;
29(10):598-607.
PMID: 37481241
Chimeric antigen receptor (CAR) T cell therapy (CAR-T) targeting the CD19 antigen on B cell acute lymphoblastic leukemia (B-ALL) has transitioned from a highly investigational therapy with limited access to...
25.
Kitko C, Bollard C, Cairo M, Chewning J, Fry T, Pulsipher M, et al.
Pediatr Blood Cancer
. 2023 Jul;
70 Suppl 6:e30577.
PMID: 37480158
Since the publication of the last Cellular Therapy and Stem Cell Transplant blueprint in 2013, Children's Oncology Group cellular therapy-based trials advanced the field and created new standards of care...
26.
Schultz L, Jacoby E, Lamble A, Maude S, McNerney K, Moskop A, et al.
Transplant Cell Ther
. 2023 Jul;
29(10):592-593.
PMID: 37442348
No abstract available.
27.
Thakar M, Logan B, Puck J, Dunn E, Buckley R, Cowan M, et al.
Lancet
. 2023 Jun;
402(10396):129-140.
PMID: 37352885
Background: Severe combined immunodeficiency (SCID) is fatal unless durable adaptive immunity is established, most commonly through allogeneic haematopoietic cell transplantation (HCT). The Primary Immune Deficiency Treatment Consortium (PIDTC) explored factors...
28.
Takahashi T, Al-Kofahi M, Jaber M, Bratrude B, Betz K, Suessmuth Y, et al.
Blood
. 2023 Jun;
142(8):700-710.
PMID: 37319437
In the ABA2 study, the T-cell costimulation blockade agent, abatacept, was safe and effective in preventing acute graft-versus-host disease (aGVHD) after unrelated-donor hematopoietic cell transplant (HCT), leading to US Food...
29.
Ma J, Morimoto K, Pulsipher M, Parekh C
JCO Precis Oncol
. 2023 Jun;
7:e2200693.
PMID: 37315262
No abstract available.
30.
Maese L, Pulsipher M
J Clin Oncol
. 2023 Jun;
41(25):4087-4092.
PMID: 37311171
Background: The Children's Oncology Group (COG) AALL1331 trial demonstrated improved survival and less toxicity in children with high-/intermediate-risk relapsed ALL receiving blinatumomab compared with intensive chemotherapy before hematopoietic stem-cell transplant...